Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NACDS In Brief

This article was originally published in The Tan Sheet

Executive Summary

Mentholatum vapor patches: Mentholatum is pulling itsWellPatch Cough and Cold Soothing Vapor Pad from the marketplace following a limited distribution launch and "weak retailer acceptance," the company said at the National Association of Chain Drug Stores Marketplace tradeshow and conference in San Diego, Calif. June 24-27. The patch was indicated for temporary relief of throat and bronchial irritation associated with a cold and provided medicated vapors that would provide relief for up to eight hours. The firm maintains that the product was not pulled for safety reasons. Novartis recently recalled its Triaminic Vapor Patch after adverse events showed the product could be linked to seizures 1("The Tan Sheet" June 26, 2006, p. 8). Mentholatum is, however, gearing up to launch WellPatch Fever. Indicated for fever reduction for both children and adults, a four-count package will be offered for $3.99...
Advertisement

Related Content

New CortiSlim Line Offers Suite Of SKUs To Boost Energy, Suppress Appetite
New CortiSlim Line Offers Suite Of SKUs To Boost Energy, Suppress Appetite
New CortiSlim Line Offers Suite Of SKUs To Boost Energy, Suppress Appetite
Triaminic Vapor Patch Adverse Events Prompt Recall By Novartis
Triaminic Vapor Patch Adverse Events Prompt Recall By Novartis

Topics

Advertisement
UsernamePublicRestriction

Register

PS099543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel